-transparent.png){kind=logo}
Mutations of proto-oncogenes are common events in the pathogenesis of cancers, as shown in a wide range of studies during the 30 years since the discovery of these genes. The benefits of novel therapies that target the products of mutant alleles in human cancers, and the demonstrated dependence of cancers in mouse models on continued expression of initiating oncogenes, are especially promising signs that revolutionary improvements in cancer care are possible. Full realization of the promise of targeted therapies, however, will require better definitions of the genotypes of human cancers, new approaches to interrupt the biochemical consequences of oncogenic mutations, and a greater understanding of drug resistance and tumor progression. In this paper, we summarize recent efforts toward these goals in our laboratory and others.
H Varmus, and
W Pao, and
K Politi, and
K Podsypanina, and
Y-C N Du
June 1985,
Anesthesiology,
H Varmus, and
W Pao, and
K Politi, and
K Podsypanina, and
Y-C N Du
April 1992,
RDH,
H Varmus, and
W Pao, and
K Politi, and
K Podsypanina, and
Y-C N Du
January 2010,
Biotechnology healthcare,
H Varmus, and
W Pao, and
K Politi, and
K Podsypanina, and
Y-C N Du
January 1993,
Journal of ophthalmic nursing & technology,
H Varmus, and
W Pao, and
K Politi, and
K Podsypanina, and
Y-C N Du
December 1993,
Lancet (London, England),
H Varmus, and
W Pao, and
K Politi, and
K Podsypanina, and
Y-C N Du
April 2002,
Cell stress & chaperones,
H Varmus, and
W Pao, and
K Politi, and
K Podsypanina, and
Y-C N Du
December 1980,
Nature,
H Varmus, and
W Pao, and
K Politi, and
K Podsypanina, and
Y-C N Du
March 2009,
PLoS genetics,
H Varmus, and
W Pao, and
K Politi, and
K Podsypanina, and
Y-C N Du
June 1998,
Trends in ecology & evolution,
H Varmus, and
W Pao, and
K Politi, and
K Podsypanina, and
Y-C N Du
November 2002,
Biochimica et biophysica acta,
